A comparative controlled trial of serum magnesium level in severe preeclamptic women between two standard magnesium sulphate regimens

Phase 4

• Conditions: Singleton, severe preeclamptic women who diagnosed over 34 completed weeks of gestation.; severe preeclampsia; magnesium sulphate; seizure prevention level

• Registration Number: TCTR20150511001
• Lead Sponsor: none

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-05-11
• Study Completion: 2015-07-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Enrolling by invitation
• Sex: Female
• Target Recruitment: 34

Inclusion Criteria

1.Singleton pregnant women who diagnosed severe preeclampsia or severe preeclampsia superimposed chronic hypertension at gestational aged over 34 completed weeks.
2.The disease treated by intravenous regimen of magnesium sulphate
3.Accepted and signed the informed consent form

Exclusion Criteria

1.Pregnant women who allegied to magnesium sulphate
2.Pregnant women who had history of chronic kidney disease or impaired renal function
3.Fatal anomaly was detected in current pregnancy
4.Pregnant women who got pregestational diabetes mellitus and gestational diabetes mellitus type A2
5.Pregnancy women who denied the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
serum magnesium level 4 hours after the treatment autometic mechine

Secondary Outcome Measures

Name	Time	Method
neonatal outcomes 24 hours after delivery observation, review medical chart, umibilical cord blood magnesium levels,maternal outcomes begin at treatment to 24 hours after delivery observation, review medical chart